June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% Efficacy in Patients with Exfoliation Syndrome (XFS) and Ocular Hypertension (OHT) or Exfoliative Glaucoma (XFG)
Author Affiliations & Notes
  • Jessica V Jasien
    New York Glaucoma Research Institute, New York, NY
    New York Eye and Ear Infirmary of Mt. Sinai, New York, NY
  • Alon Skaat
    Glaucoma Associates of New York, New York, NY
    New York Eye and Ear Infirmary of Mt. Sinai, New York, NY
  • Robert Ritch
    New York Glaucoma Research Institute, New York, NY
    New York Eye and Ear Infirmary of Mt. Sinai, New York, NY
  • Footnotes
    Commercial Relationships Jessica Jasien, None; Alon Skaat, None; Robert Ritch, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5713. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jessica V Jasien, Alon Skaat, Robert Ritch; Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% Efficacy in Patients with Exfoliation Syndrome (XFS) and Ocular Hypertension (OHT) or Exfoliative Glaucoma (XFG). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5713.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Elevated intraocular pressure (IOP) is the sole proven modifiable risk factor for XFG development and progression. Rho-associated protein kinase inhibitors have been studied for their ability to lower IOP, by several mechanisms including disruption of adhesions between the trabecular meshwork (TM) cells and increasing aqueous outflow. The main purpose of this study was to evaluate the efficacy of AR-12286 and evaluate the lasting effect on IOP after discontinuation.

 
Methods
 

Double-blind, interventional study, study eye of 6 men and 4 women was randomized to AR-12286 0.5% or 0.7% adjunctive to current IOP lowering regimen for 6 months. Visits included baseline, 1 week, 1 and 3 months; at 3 months AR-12286 was discontinued for one week and was resumed at week 13. At the 6 month visit, AR-12286 was discontinued, with final visit at week 25.

 
Results
 

The study eye mean baseline IOP was 25±2.4mmHg, mean IOP reduced to 19.1±2.3 mmHg at 1 week (P<0.001), 17.5±3.6 mmHg at 1 month (P<0.001), and 17.4±3.6 mmHg at 3 months (P<0.001), yielding an average IOP reduction of 26.8%, 35.3% and 35.8% respectively. At the 13 week visit, after AR-12286 was discontinued, mean IOP increased to 21.6±5.4 mmHg (P=0.06 compared to baseline). At 6 months, the mean IOP was 21.8±7.8 mmHg (P=0.2), and AR-12286 was discontinued. At week 25 the mean IOP was 21.3±5.3 mmHg (P=0.06).

 
Conclusions
 

AR-12286 was well tolerated and provided clinically statistical significant ocular hypotensive efficacy with XFS and OHT or XFG patients. This drug may represent a new therapeutic paradigm for the treatment of XFG.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×